321 related articles for article (PubMed ID: 31424026)
21. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
Tamas EF; Epstein JI
Am J Surg Pathol; 2006 Aug; 30(8):980-5. PubMed ID: 16861969
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
23. Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer.
Goldberg H; Ramiz AH; Glicksman R; Salgado NS; Chandrasekar T; Klaassen Z; Wallis CJD; Hosni A; Moraes FY; Ghai S; Kulkarni GS; Hamilton RJ; Perlis N; Toi A; Chung P; Evans A; van der Kwast T; Finelli A; Fleshner N; Berlin A
Eur Urol Oncol; 2019 Feb; 2(1):88-96. PubMed ID: 30929849
[TBL] [Abstract][Full Text] [Related]
24. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
25. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
Tsuzuki T; Hernandez DJ; Aydin H; Trock B; Walsh PC; Epstein JI
J Urol; 2005 Feb; 173(2):450-3. PubMed ID: 15643200
[TBL] [Abstract][Full Text] [Related]
26. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
Abdel-Rahman O; Cheung WY
Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
[TBL] [Abstract][Full Text] [Related]
27. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Zhu S; Zhao JG; Chen JR; Liu ZH; Sun GX; Wang ZP; Ni YC; Dai JD; Shen PF; Zeng H
Asian J Androl; 2020; 22(5):519-525. PubMed ID: 31710002
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
29. Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multi-institutional analysis.
Barsky AR; Kraus RD; Carmona R; Santos PMG; Li C; Schwartz LE; Ballas LK; Vapiwala N
Cancer Med; 2020 May; 9(10):3383-3389. PubMed ID: 32187859
[TBL] [Abstract][Full Text] [Related]
30. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
[TBL] [Abstract][Full Text] [Related]
31. Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassification.
Ball MW; Partin AW; Epstein JI
Urology; 2015 Jan; 85(1):161-4. PubMed ID: 25440818
[TBL] [Abstract][Full Text] [Related]
32. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
34. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
[TBL] [Abstract][Full Text] [Related]
36. Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.
Zhao J; Sun G; Liao B; Zhang X; Armstrong CM; Yin X; Liu J; Chen J; Yang Y; Zhao P; Tang Q; Wang Z; Chen Z; Li X; Wei Q; Li X; Chen N; Gao AC; Shen P; Zeng H
BJU Int; 2018 Dec; 122(6):994-1002. PubMed ID: 29772102
[TBL] [Abstract][Full Text] [Related]
37. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
[TBL] [Abstract][Full Text] [Related]
39. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer.
Wheeler TM; Dillioglugil O; Kattan MW; Arakawa A; Soh S; Suyama K; Ohori M; Scardino PT
Hum Pathol; 1998 Aug; 29(8):856-62. PubMed ID: 9712429
[TBL] [Abstract][Full Text] [Related]
40. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
